XTL to acquire 85% of Beyond Air's NeuroNOS for equity, $1M cash, up to $32.5M milestones

Beyond Air, Inc.

XTL acquires 85% of NeuroNOS for 19.9% of XTL's share capital, $1M cash, and up to $32.5M in milestone payments.
NeuroNOS platform targets core autism pathophysiology; two Nobel Laureates join scientific team.
NeuroNOS holds two FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma.
Beyond Air becomes significant XTL shareholder, retains 15% of NeuroNOS; deal valued up to $32.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.